Supports· strongORCH-E015
A single GABA_A β3 point mutation abolishes intravenous anesthetic action in vivo
- what the source states
- The abstract reports that mice carrying the β3(N265M) point mutation, which renders GABA_A receptors containing the β3 subunit insensitive to etomidate and propofol, showed abolished immobilizing action of both drugs and a profound reduction in their hypnotic effect (duration of loss of righting reflex). The same mutation only slightly reduced the effects of the volatile anesthetics enflurane and halothane. The authors conclude that the volatile agents "act via a broader spectrum of molecular targets."
- what we infer
- The steelman anchor, and the reason the conventional account is assessed as well supported: this is target-level causal evidence of a kind no microtubule study in this case approaches — change one residue, lose the drug effect. Any serious treatment of Orch OR has to reckon with the fact that its main rival has this and it does not. The record is filed as supporting ORCH-C003 and undermining the strong anesthesia claim, but with an honest boundary: the result is about intravenous agents, and the authors' own conclusion about volatiles acting through a broader target spectrum is the specific opening through which a microtubule contribution to volatile anesthesia could still enter. Orch OR proponents are entitled to that opening; they are not entitled to ignore the rest.
- limitations
- Establishes the mechanism for etomidate and propofol; does not transfer to volatile agents, which are the agents most Orch OR experiments use.
- Shows a target is necessary for these drugs' action, not that consciousness is exhausted by receptor pharmacology.
- Cautionary precedent from the same literature: TREK-1 knockout anesthetic resistance was initially reported and later not reproduced, so genetic anesthetic-target findings are not automatically durable.